SCHEMBL16058199

SCHEMBL16058199

Cc1c(-c2ccc(C(=O)NC3CCCCC3)cc2)ccnc1OC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.51
▸ RAB9A P51151 5/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ HPGD P15428 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ CYP46A1 Q9Y6A2 1/20 0.47
▸ MAPK14 Q16539 2/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.46
▸ KMT2A Q03164 3/20 0.44
▸ PTPN1 P18031 1/20 0.44
▸ PTPN11 Q06124 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CNR1 P21554 1/20 0.43
▸ CNR2 P34972 1/20 0.43
▸ MAPKAPK2 P49137 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16057783 0.79 APP (0.45) NPC1RAB9ASMN1; SMN2
SCHEMBL16058275 0.76 GSK3A (0.49) NPC1RAB9ASMN1; SMN2HPGDMAPK14
SCHEMBL16057040 0.75 RAB9A (0.44) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL16056911 0.73 ACACB (0.35) CYP1A2CYP2C19KMT2AMEN1
SCHEMBL16058198 0.73 CNR2 (0.53) NPC1RAB9ASMN1; SMN2MAPTCNR1
SCHEMBL518043 0.72 NPC1 (0.74) NPC1RAB9ASMN1; SMN2HPGDCYP1A2
SCHEMBL29927547 0.72 NPC1 (0.74) NPC1RAB9ASMN1; SMN2HPGDCYP1A2
SCHEMBL517912 0.72 NPC1 (0.74) NPC1RAB9ASMN1; SMN2HPGDCYP1A2
SCHEMBL517178 0.72 NPC1 (0.74) NPC1RAB9ASMN1; SMN2HPGDCYP1A2
SCHEMBL14082292 0.72 NPC1 (0.62) NPC1RAB9ASMN1; SMN2HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 NPC1 403/4885RAB9A 1289/4885SMN1; SMN2 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback